MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. RDY, ASND, MRNA, VTRS, QGEN, ROIV, LNTH, RVMD, BBIO, and LEGNShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech MorphoSys (NASDAQ:MOR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Is MOR or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 17.87% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Dr. Reddy's Laboratories 17.25%17.87%12.32% Does the media prefer MOR or RDY? In the previous week, Dr. Reddy's Laboratories had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 0 mentions for MorphoSys. Dr. Reddy's Laboratories' average media sentiment score of 1.14 beat MorphoSys' score of 0.00 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Dr. Reddy's Laboratories Positive Do analysts rate MOR or RDY? Dr. Reddy's Laboratories has a consensus target price of $17.00, suggesting a potential upside of 22.79%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, MOR or RDY? MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Does the MarketBeat Community favor MOR or RDY? Dr. Reddy's Laboratories received 296 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 59.33% of users gave Dr. Reddy's Laboratories an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformMorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Dr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Which has preferable valuation and earnings, MOR or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Dr. Reddy's Laboratories$311.31B0.04$668M$0.6321.98 Do insiders and institutionals have more ownership in MOR or RDY? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryDr. Reddy's Laboratories beats MorphoSys on 15 of the 18 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$6.85B$5.54B$7.93BDividend YieldN/A2.97%5.09%4.22%P/E Ratio-5.457.3222.5518.54Price / Sales11.99241.43395.25103.29Price / CashN/A65.8538.1834.62Price / Book54.176.486.764.25Net Income-$205.35M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.58%1.37%1.03%1 Month PerformanceN/A5.00%2.77%2.70%1 Year Performance6.10%-3.72%15.59%4.05% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730RDYDr. Reddy's Laboratories1.8412 of 5 stars$13.68+0.1%$17.00+24.3%-6.5%$11.42B$311.31B21.7824,800Upcoming EarningsPositive NewsASNDAscendis Pharma A/S2.3081 of 5 stars$161.15-2.4%$204.67+27.0%+18.8%$9.83B$363.64M-22.70640News CoverageMRNAModerna4.3466 of 5 stars$25.13+1.7%$58.70+133.6%-75.7%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.6837 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.8104 of 5 stars$40.51-0.5%$47.83+18.1%+1.4%$9.01B$1.98B112.806,030Upcoming EarningsROIVRoivant Sciences2.1942 of 5 stars$10.04-1.1%$17.50+74.3%+3.3%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9716 of 5 stars$100.62-0.7%$129.43+28.6%+57.2%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.7504 of 5 stars$36.56-0.5%$66.67+82.3%+4.7%$6.80B$742,000.00-10.18250Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5565 of 5 stars$33.51-1.1%$53.00+58.2%+42.1%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLEGNLegend Biotech2.6714 of 5 stars$32.24-1.7%$79.00+145.0%-22.8%$5.92B$627.24M-33.941,070Positive News Related Companies and Tools Related Companies RDY Competitors ASND Competitors MRNA Competitors VTRS Competitors QGEN Competitors ROIV Competitors LNTH Competitors RVMD Competitors BBIO Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MOR Stock Free MOR Stock Alerts